Prevention or treatment of malaria.
Treat symptoms of lupus erythematosus and rheumatoid arthritis.
Important note: The FDA revoked the Emergency Use Authorization for hydroxychloroquine in hospitalized patients for COVID-19 on June 15, 2020. The FDA determined that hydroxychloroquine is unlikely to be effective in treating COVID-19.
Malaria: termination of acute malarial attack or absence of or reduced malarial parasite count on blood smear may indicate efficacy.
Systemic lupus erythematosus/rheumatoid arthritis: improvement in C-reactive protein levels and erythrocyte sedimentation rate may indicate efficacy.
Monitor renal and hepatic functions.
Monitor ECG, electrolytes, renal function, and hepatic function at baseline and during therapy.
Perform ophthalmologic examination in all patients beginning long-term therapy within the first year; repeat screening annually.
Common
Serious
Contraindications:
Multiple drug-drug interactions:
Antimicrobial class: Aminoquinoline
Average serum half life: 40-50 days (chronic use)
Precautions: